Angelita Rebamontan Domingo Sells 2,585 Shares of Pro-Dex, Inc. (NASDAQ:PDEX) Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Angelita Rebamontan Domingo sold 2,585 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $18.30, for a total value of $47,305.50. Following the transaction, the director now owns 8,191 shares in the company, valued at $149,895.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Pro-Dex Stock Performance

Shares of Pro-Dex stock traded up $0.29 during trading on Wednesday, reaching $18.89. The company’s stock had a trading volume of 1,595 shares, compared to its average volume of 7,600. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.08 and a current ratio of 3.45. The business’s fifty day moving average price is $19.06 and its 200-day moving average price is $18.64. The firm has a market cap of $64.60 million, a price-to-earnings ratio of 32.12 and a beta of 0.41. Pro-Dex, Inc. has a one year low of $14.51 and a one year high of $22.99.

Pro-Dex (NASDAQ:PDEX) last released its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.19 earnings per share for the quarter. Pro-Dex had a return on equity of 6.50% and a net margin of 4.13%. The business had revenue of $14.29 million for the quarter.

Institutional Investors Weigh In On Pro-Dex

An institutional investor recently raised its position in Pro-Dex stock. Perritt Capital Management Inc. increased its stake in Pro-Dex, Inc. (NASDAQ:PDEX) by 43.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,000 shares of the medical instruments supplier’s stock after purchasing an additional 1,813 shares during the period. Perritt Capital Management Inc. owned 0.18% of Pro-Dex worth $106,000 as of its most recent SEC filing. 15.28% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 5th.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.